What’s the current market cap for Fulcrum Therapeutics stock?

Fulcrum Therapeutics (FULC) has a market cap of $461M as of May 30, 2026.

What is the P/E ratio for Fulcrum Therapeutics stock?

The price to earnings (P/E) ratio for Fulcrum Therapeutics (FULC) stock is 0 as of May 30, 2026.

Does Fulcrum Therapeutics stock pay dividends?

No, Fulcrum Therapeutics (FULC) stock does not pay dividends to its shareholders as of May 30, 2026.

When is the next Fulcrum Therapeutics dividend payment date?

Fulcrum Therapeutics (FULC) stock does not pay dividends to its shareholders.

What is the beta indicator for Fulcrum Therapeutics?

Fulcrum Therapeutics (FULC) has a beta rating of 3.27. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

Buy Fulcrum Therapeutics stock | $FULC Share Price

13:30

15:10

16:45

18:25

20:00

About Fulcrum Therapeutics

Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing small molecules for genetically defined rare diseases. Its product candidate, Pociredir, is an oral small molecule designed to induce fetal hemoglobin (HbF) and is in clinical development for sickle cell disease (SCD). The company completed dosing in the Phase 1b PIONEER trial evaluating pociredir in adults with SCD and reported clinical data showing clinically relevant HbF induction and improvements in markers of hemolysis and anemia. The company has also generated a pipeline of clinical-stage and pre-clinical programs targeting the root causes of rare genetic diseases.

Ticker

$FULC

Sector

Health

Primary listing

NASDAQ

Employees

Headquarters

Cambridge, United States

Website

www.fulcrumtx.com

FULC Metrics

BasicAdvanced

$461m

-$1.14

3.27

What the Analysts think about FULC

Analyst ratings (Buy, Hold, Sell) for Fulcrum Therapeutics stock.

Bulls say / Bears say

Phase 1b PIONEER data from the 20 mg cohort showed an average absolute increase in fetal hemoglobin of 9.9% at Week 6 compared to 5.6% at the 12 mg dose, with 58% of patients reaching at least 20% HbF, confirming strong target engagement and a clear dose response (SEC)

Key indicators of hemolysis and anemia improved at Week 6—bilirubin and LDH each fell 37%, reticulocyte counts dropped 33%, and hemoglobin increased by 0.8 g/dL—signaling better red blood cell health and less hemolysis (SEC)

Pociredir has received FDA Fast Track and Orphan Drug Designations for sickle cell disease, enabling expedited development timelines and possible market exclusivity incentives (NASDAQ)

Intense competition from gene-editing therapies could limit pociredir’s market potential, as Intellia’s CRISPR-based treatment for a rare disease met its late-stage trial goal in April 2026, highlighting a one-time curative approach that may overshadow small-molecule therapies (Bloomberg)

Regulatory unpredictability poses approval risks, evidenced by the FDA’s rejection of Disc Medicine’s bitopertin for a rare genetic disorder just months after receiving priority review, underscoring potential delays for fulcrum’s pociredir regulatory pathway (Bloomberg)

Fulcrum acknowledges the need to raise substantial additional capital to advance its clinical programs, which could lead to future dilution and shareholder pressure if equivalent financings cannot be secured at favorable terms (SEC)

Data summarised monthly by Lightyear AI. Last updated on 12 May 2026.

FULC Financial Performance

Revenues and expenses

QuarterlyAnnual

Q3 24

QoQ growth

Revenue

$37bn

-39.75%

Net income

$45bn

107.52%

Profit margin

37.65%

6.78%

FULC Earnings Performance

Company profitability

QuarterlyAnnual

Q4 23

Q1 24

Q2 24

Q3 24

Q4 24

Actual

$3.69

$2.85

$2.45

$2.42

Expected

$3.55

$2.61

$2.05

$2.31

$3.94

Surprise

3.94%

9.20%

19.51%

4.63%

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $FULC

Capital at risk

Market closed

Upcoming events

No upcoming events

Bulls say / Bears say

Pociredir has received FDA Fast Track and Orphan Drug Designations for sickle cell disease, enabling expedited development timelines and possible market exclusivity incentives (NASDAQ)

Data summarised monthly by Lightyear AI. Last updated on 12 May 2026.

About Fulcrum Therapeutics

Ticker

Employees

FULC Metrics

Price and volume

Financial strength

Profitability

Management effectiveness

Valuation

Growth

What the Analysts think about FULC

Analyst Ratings

Bulls say / Bears say

FULC Financial Performance

Income Statement

FULC Earnings Performance

Earnings per share (EPS)

Buy $FULC

Upcoming events

No upcoming events

Lightyear

Legal

Work with us

Bulls say / Bears say

Fulcrum Therapeutics/$FULC

About Fulcrum Therapeutics

Ticker

Employees

FULC Metrics

Price and volume

Financial strength

Profitability

Management effectiveness

Valuation

Growth

What the Analysts think about FULC

Analyst Ratings

Bulls say / Bears say

FULC Financial Performance

Income Statement

FULC Earnings Performance

Earnings per share (EPS)

Buy $FULC

Upcoming events

No upcoming events

What’s the current market cap for Fulcrum Therapeutics stock?

What is the P/E ratio for Fulcrum Therapeutics stock?

Does Fulcrum Therapeutics stock pay dividends?

When is the next Fulcrum Therapeutics dividend payment date?

What is the beta indicator for Fulcrum Therapeutics?

Bulls say / Bears say